SUO 2024
SUO 2024
Advertisement
Katie KoskoSUO 2024 | December 5, 2024
Prostate-specific antigen (PSA) velocity and PSA values taken together may improve the specificity of monitoring.
Read More
Katie KoskoSUO 2024 | December 5, 2024
Patients and survivors who engaged in physical activity experienced a protective effect on mental health.
Katie KoskoSUO 2024 | December 4, 2024
Contaminants, such as heavy metals, pesticides, and microbial pathogens, may influence cancer severity.
Katie KoskoSUO 2024 | December 4, 2024
Patients and caregivers most valued the role of genetics in understanding risk stratification.
Katie KoskoSUO 2024 | December 4, 2024
In lower-income countries, intravesical therapies for bladder cancer can match or exceed median household incomes.
Katie KoskoSUO 2024 | December 3, 2024
Women had an 89% match rate in urologic oncology fellowships, compared with 54% in men.
Katie KoskoSUO 2024 | December 2, 2024
The rate of prostate cancer mortality is higher in parts of the United States where structural racism is also higher.
Katie KoskoSUO 2024 | December 2, 2024
The slower recovery PSA screening rate in Black men highlights the persistent racial disparities in health care access.
Katie KoskoSUO 2024 | November 27, 2024
In this analysis, the model performed best for predicting survival Asian patients and worst for Non-Hispanic Black patients.
Katie KoskoSUO 2024 | November 26, 2024
Hispanic men who are Black or Cuban had the lowest rates of prostate-specific antigen screening.
Katie KoskoSUO 2024 | November 26, 2024
Race-associated tumor differences can affect early diagnostic testing and targeted therapeutics.
Katie KoskoSUO 2024 | November 25, 2024
Only half of patients received timely follow-up, and 34% received no follow-up at all.
Advertisement
Advertisement
Advertisement
Latest News

December 12, 2024